Australia's most trusted
source of pharma news
Tuesday, 14 April 2026
Posted 10 April 2026 PM
Things are heating up in the local obesity market with two companies falling foul of the Medicines Australia Code of Conduct, and fined a combined $210,000.
A Novo Nordisk complaint resulted in a $130,000 fine for Eli Lilly which in turn counterclaimed resulting in an $80,000 fine for Novo.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.